Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrija Bogdanovic

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Experimental Cell Research|June 8, 2014
Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cellsBiljana Ristic, Mihajlo Bosnjak, Katarina Arsikin, et al.
Chemical Research in Toxicology|March 10, 2012
Cyclohexyl analogues of ethylenediamine dipropanoic acid induce caspase-independent mitochondrial apoptosis in human leukemic cellsSonja Misirlic Dencic, Jelena Poljarevic, Urosh Vilimanovich, et al.
Advances in Therapy|April 4, 2024
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension StudyChristopher J Patriquin, Andrija Bogdanovic, Morag Griffin, et al.
Cancers|January 8, 2025
Risk Factors for Venous Thromboembolism in Acute Promyelocytic LeukemiaNikica Sabljic, Nikola Pantic, Marijana Virijevic, et al.
Frontiers in Pharmacology|January 20, 2025
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challengesSofija Kozarac, Jelena Ivanovic, Marko Mitrovic, et al.
Annals of Hematology|July 22, 2022
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuriaRaymond S M Wong, Humphrey W H Pullon, Ismail Amine, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
American Journal of Hematology|August 29, 2019
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobinMichael Lauseker, Katharina Bachl, Anna Turkina, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Experimental Cell Research|June 8, 2014
Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cellsBiljana Ristic, Mihajlo Bosnjak, Katarina Arsikin, et al.
Chemical Research in Toxicology|March 10, 2012
Cyclohexyl analogues of ethylenediamine dipropanoic acid induce caspase-independent mitochondrial apoptosis in human leukemic cellsSonja Misirlic Dencic, Jelena Poljarevic, Urosh Vilimanovich, et al.
Advances in Therapy|April 4, 2024
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension StudyChristopher J Patriquin, Andrija Bogdanovic, Morag Griffin, et al.
Cancers|January 8, 2025
Risk Factors for Venous Thromboembolism in Acute Promyelocytic LeukemiaNikica Sabljic, Nikola Pantic, Marijana Virijevic, et al.
Frontiers in Pharmacology|January 20, 2025
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challengesSofija Kozarac, Jelena Ivanovic, Marko Mitrovic, et al.
Annals of Hematology|July 22, 2022
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuriaRaymond S M Wong, Humphrey W H Pullon, Ismail Amine, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
American Journal of Hematology|August 29, 2019
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobinMichael Lauseker, Katharina Bachl, Anna Turkina, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Pageof 6